Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Chemoradiation with Paclitaxel, Carboplatin, and 5-FU for Esophageal Cancer
NCT00022139Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2002
- Primary completion
- Jul 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, carboplatin and fluorouracil in esophageal cancer and gastroesophageal junction cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: Pathologic Complete Response Rate up to 4 years. Started Jan 2002; status: completed.
02
Drugs
paclitaxelcarboplatinfluorouracil
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00022139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022139.